payment

Creative Medical Technology secured approximately $4.2 million in gross proceeds through the immediate exercise of 1,116,136 previously issued, registered...

RenovoRx has initiated its PanTheR post-marketing registry with the first registry-eligible patient procedure completed at the University of Vermont...

Mapi Pharma has enrolled the first patient in a multinational Phase I/II study of its once-monthly injectable cariprazine for...

Keros Therapeutics initiated Phase 3 trials for elritercept, a treatment for transfusion-dependent anemia in patients with myelodysplastic syndromes (MDS)....

Daré Bioscience announced positive interim safety and efficacy results from its Phase 3 clinical trial of Ovaprene, a hormone-free,...

SCYNEXIS has restarted patient dosing in its Phase 3 MARIO study of oral ibrexafungerp for invasive candidiasis after resolving...

CRISPR Therapeutics and Sirius Therapeutics have partnered to develop and commercialize SRSD107, a long-acting siRNA therapy for thromboembolic disorders....

Nxera Pharma’s partner, Neurocrine Biosciences, has launched a Phase 3 trial for NBI-1117568, an oral M4 selective receptor agonist,...

Nurix Therapeutics announced FDA clearance of the Investigational New Drug (IND) application for GS-6791/NX-0479, an IRAK4 degrader. This allows...

Alumis and Kaken Pharmaceutical have partnered to develop and commercialize ESK-001, a selective TYK2 inhibitor, for dermatological conditions in...